Pinter, A. http://orcid.org/0000-0002-1330-1502
Costanzo, A.
Khattri, S.
Smith, S. D.
Carrascosa, J. M.
Tada, Y.
Riedl, E.
Reich, A.
Brnabic, A.
Haustrup, N.
Lampropoulou, A.
Lipkovich, I.
Kadziola, Z.
Paul, C.
Schuster, C.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 9 November 2023
Accepted: 8 December 2023
First Online: 19 December 2023
Change Date: 30 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-024-01105-3
Declarations
:
: Andreas Pinter has served as an investigator, speaker, and/or consultant for AbbVie, Almirall-Hermal, Amgen, Biogen Idec, BioNTech, Boehringer Ingelheim, Celgene, GSK, Eli Lilly and Company, Galderma, Hexal, Janssen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough and UCB Pharma. Antonio Costanzo served as advisory board member and consultant, and/or has received fees and/or speaker’s honoraria and/or has participated to clinical trials for Abbvie, Almirall, Amgen, Eli Lilly and Company, Janssen, Novartis, Sanofi and UCB and is president of European Dermatology Forum and has received payment to participate on the advisory boards for IQVIA. Saakshi Khattri reports grants from Pfizer, Incyte and Acelyrin and has worked as a consultant and/or served on the speaker’s bureau for Abbvie, Arcutis, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Leo Pharma, Novartis, Regeneron, Sanofi and UCB Pharma. Adam Reich has worked as a consultant or speaker for Abbvie, Bausch Health, Bioderma, Celgene, Chema Elektromet, Eli Lilly and Company, Galderma, Janssen, LeoPharma, Medac, Novartis, Pierre Fabre, Pfizer, Trevi and Sandoz and participated as principal investigator or sub-investigator in clinical trials sponsored by AnaptysBio, Arcutis, Argenx, Biothera, Celltrion, Drug delivery solutions, Galderma, Genentech, Inflarx, Incyte, Janssen, Kymab Limited, LeoPharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Eli Lilly and Company, UCB and VielaBio. Jose-Manuel Carrascosa, reports grants, personal fees, participation on advisory boards and/or non-financial support from Abbvie, Almirall, Amgen, Boehringer Ingelheim, BMS, Eli Lilly and Company, Janssen, Novartis, Sandoz, Leo-pharma. Saxon Smit has worked as an advisor and/or speaker for Abbvie, UCB, Sanofi Gezyme, Novartis, Eli Lilly and Company, BMS and Pfizer; and participated in data safety monitoring board or advisory boards for BMS, Novartis, Eli Lilly and Company, Abbvie, Sanofi Genzyme, Leo Pharma, UCB and Amgen. Yayoi Tada reports grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly and Company, Jimro, Kaken, Kyowa Kirin, LEO Pharma, Maruho, Meiji Seika Pharma, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii, and UCB and has received honoraria for speaking events from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly and Company, Janssen Pharma, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Novartis Pharma, Sun Pharma, Taiho, Tanabe-Mitsubishi, Torii, and UCB. Elisabeth Riedl is a former employee, minor stockholder and has pending patents with Eli Lilly and Company and has also been a speaker and/or consultant for Eli Lilly and Company and Pehpharma. Carle Paul has served as a consultant for Almirall, Abbvie, Amgen, BMS, Boeheringer Ingelheim, Celgene, GSK, Janssen, Leo Pharma, Eli Lilly and Company, Merck, Novartis, Pfizer, Sanofi and UCB; received support for attending meetings and/or travel from Janssen; participated on a data safety monitoring board or advisory board with IQVIA (DSMB). Alan Brnabic, Anastasia Lampropoulou, Natalie Haustrup, Ilya Lipkovich, Zbigniew Kadziola, and Christopher Schuster are all employees and minor shareholders of Eli Lilly and Company.
: The protocol, amendments, and consent documentation were approved by local institutional review boards (IRB). The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207) and was conducted according to International Conference on Harmonization, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study. We confirm that the necessary central or local IRB and/or ethics committee approvals have been obtained for this multi-site, international study by United BioSource LLC (UBC). Approvals can be provided on request.